Novo Nordisk to buy Prothena’s heart drug in deal worth up to $1.2 bln
July 12 (Reuters) – Danish drugmaker Novo Nordisk (NOVOb.CO) will acquire U.S. drug developer Prothena Corp’s (PRTA.O) experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday. The acquisition is in line with Novo’s strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it […]
Roche buys GenMark for $1.8 million to challenge test rivals
ZURICH (Reuters) – Roche is filling a testing portfolio gap by buying U.S.-based GenMark Diagnostics in a $1.8 billion deal that the Swiss pharmaceuticals manufacturer said taps one of the fastest-growing diagnostics areas.
